Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

NCT00002816 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2013-08-22

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.

Conditions

Interventions

DRUG

cytarabine

Given IV

DRUG

dexamethasone

Given IV

DRUG

etoposide

Given IV

DRUG

idarubicin

Given IV

DRUG

ifosfamide

Given IV

DRUG

leucovorin calcium

DRUG

mesna

Given IV

DRUG

pegaspargase

Given IV

DRUG

therapeutic hydrocortisone

DRUG

thioguanine

DRUG

vincristine sulfate

Given IV

RADIATION

low-LET cobalt-60 gamma ray therapy

RADIATION

low-LET electron therapy

RADIATION

low-LET photon therapy

DRUG

Methotrexate

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Michael L.N. Willoughby, MD · Princess Margaret Hospital for Children

Study Design

Purpose
TREATMENT

Eligibility

Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-12-31
Primary Completion
2002-11-30
Completion
2006-04-30

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002816 on ClinicalTrials.gov